This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Assertio (ASRT) Q4 Earnings Lag Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.
Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.
Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
by Zacks Equity Research
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
by Kinjel Shah
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover
by Zacks Equity Research
Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Stock gains.
Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Assertio (ASRT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Homology Medicines (FIXX) have performed compared to their sector so far this year.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, Assertio (ASRT) Is Still a Bargain Stock
by Zacks Equity Research
Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.
Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study
by Zacks Equity Research
ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
by Zacks Equity Research
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 300.00% and 15.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 9th
by Zacks Equity Research
ASRT, CVGW, NTRB, ITRG, and KNBWY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2021
New Strong Sell Stocks for September 7th
by Zacks Equity Research
ASRT, GLDD, MOGO, XPO, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on September 7, 2021
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -300.00% and 24.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options
by Aditi Saraogi
Investors need to pay close attention to for Assertio Holdings (ASRT) stock based on the movements in the options market lately.
Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.